logo-loader
RNS
MaxCyte Inc

MaxCyte, Inc. - Result of Annual General Meeting

RNS Number : 5470N
MaxCyte, Inc.
19 June 2025
 

A black letter on a white background AI-generated content may be incorrect.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON PUBLICATION OF THIS ANNOUNCEMENT, THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

MaxCyte Inc.

("MaxCyte" or the "Company")

Result of Annual General Meeting

 

ROCKVILLE, Md., LONDON, UK, 19 June, 2025 MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics today announces that at its Annual General Meeting held yesterday, all resolutions were duly passed.

The full text of the resolutions proposed and passed at the Annual General Meeting can be found in the proxy statement which was published and posted to stockholders on April 28, 2025 and copies of which are available in the SEC's EDGAR filing database on the SEC's website at www.sec.gov. 

AIM Delisting

Among the resolutions passed by stockholders was a resolution for the cancellation of the admission of the Company's Common Stock to trading on AIM. Accordingly, it is expected that the last day of dealings in the Company's Common Stock on AIM will be 25 June 2025 and that the cancellation of their admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June 2025.

Following the delisting, there will be no public market in the United Kingdom on which the Common Stock can be traded, however the Company will retain its U.S. listing of Common Stock on the Nasdaq Global Select Market ("Nasdaq") under ticker symbol MXCT.

Further information regarding the delisting, including arrangements for how investors can continue to trade the Company's Common Stock on Nasdaq and other 'frequently asked questions', can be found at: https://investors.maxcyte.com/static-files/529f4a8b-c6e9-4db6-bfc1-6a2da9f0252a

Maher Masoud, President and CEO of MaxCyte commented: "I would like to thank our shareholders for their support since the Company's AIM listing in 2016. The belief and continued commitment from our U.K. investors in our vision of enabling cell and gene therapies allowed us to have the foundation to become the only cell-engineering technology used in the engineering of a commercial non-viral gene edited product. While we will be a Nasdaq only listed company, all of our shareholders have my commitment to our continued engagement. Cell and gene therapies are the future of medicine, and with the continued support from our shareholders, MaxCyte's leading non-viral cell-engineering platform with SeQure's DX's gene editing risk assessment services will help drive precision medicine forward."

For further information, please contact:

 


MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

 

 

+1 415-937-5400

ir@maxcyte.com

 



Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Mark Rogers

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500



 

UK IR Adviser

ICR Healthcare

Mary-Jane Elliott

Chris Welsh 

 

+44 (0)203 709 5700

maxcyte@icrhealthcare.com

 


 

Additional Information

The person responsible for arranging the release of this information on behalf of the Company is David Sandoval, General Counsel.

 

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGGUGDLUXBDGUC
NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.

It is important for you to know that:

(a) none of the Content is, or is intended to be, general or personal advice

(b) the principal purpose of the Content is to provide factual information only and to comment on news;

(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;

(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and

(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.

The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.

In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read